Related Articles
Asia
Hansoh Pharma Gets China Nod for Trial of Tumor Drug
Hansoh Pharmaceutical's (HKG:3692) obtained clinical trial approval for its HS-10541 tablets from China's National Medical Products Administration, according to a Wednesday Hong Kong bourse filing.Shares of the pharma firm were down over 1% in Thursday afternoon trading.The trial will study the drug for the treatment of patients with KRAS G12C-mutated advanced solid tumors.
$HKG:3692
Asia
Kehua Bio-Engineering's Unit Gets Registration Certificate for Metapneumovirus Nucleic Acid Kit
Shanghai Kehua Bio-Engineering's (SHE:002022) unit, Suzhou Tianlong Biotechnology, received a medical device registration certificate from China's National Medical Products Administration for a swab kit for metapneumovirus nucleic acid, according to a Shenzhen bourse filing on Thursday.The certificate for the human metapneumovirus nucleic acid detection kit is valid until May 10, 2031.The Chinese in vitro diagnostics company's shares fell 2% during the afternoon trade.
$SHE:002022
Asia
CTBC Financial Books NT$5.4 Billion Profit in April
CTBC Financial (TPE:2891) booked a consolidated net profit of NT$5.40 billion for April, with pre-tax income of NT$6.58 billion, or according to a Thursday Taiwan Exchange filing.For the first four months of 2026, the group recorded an attribuatble net profit of NT$28.5 billion, or NT$1.46 per share.Meanwhile, cumulativewhile pre-tax income came in at NT$34.9 billion, the filing said.
$TPE:2891